Nanologica AB has engaged two senior scientific advisors within the field of respiratory drug delivery, for the purpose of advancing the NLAB Spiro™ inhalation platform further. Dr. John Pritchard has more than 40 years of experience from the inhalation industry working in various positions, leading and managing global portfolios of technology projects from discovery to
Nanologicas bokslutskommuniké kommer att publiceras fredagen den 26 februari, istället för den 19 februari som tidigare meddelats. Datum för kommande finansiella rapporter: Bokslutskommuniké 2020 26 februari, 2021 Årsredovisning 2020 23 april, 2021 Delårsrapport jan-mar 2021
The first samples of test material from the upscaling to large-scale production of Nanologica’s silica have been delivered. Upscaling to large-scale production of Nanologica’s silica started in July 2019. The silica is produced according to Nanologica’s proprietary methods at the contract manufacturer Sterling Pharma Solutions in the UK. The first samples of test material have
Nanologica is a public company listed for trade on Spotlight Stock Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
Company presentation made by CEO Andreas Bhagwani on May 28, 2019.
For more videos about the Company as well as video presentations of interim reports, please refer to Investor Relations.
